Chemoprevention of head and neck cancer

Journal of the Medical Association of Thailand

Volumn 79, Issue 3, 1996, Pages

  Voravud, Narin ^a  

^a CHULALONGKORN UNIVERSITY   (Thailand)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCYSTEINE; ANTIOXIDANT; BETA CAROTENE; ETRETINATE; ISOTRETINOIN; RETINOIC ACID; RETINOID; RETINOL; SELENIUM;

CANCER PREVENTION; CARCINOGENESIS; DRUG EFFECT; HEAD AND NECK CANCER; HUMAN; NONHUMAN; PAPILLOMATOSIS; REVIEW;

ANTICARCINOGENIC AGENTS; CARCINOMA, SQUAMOUS CELL; CLINICAL TRIALS; HEAD AND NECK NEOPLASMS; HUMANS; LEUKOPLAKIA, ORAL; PAPILLOMA; PRECANCEROUS CONDITIONS; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 18544403952     PISSN: 01252208     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (65)

1. Boring CC, Squires TS, Tong T. Cancer statistics. Ca Cancer J Clin 1992; 42; 19-38.
2. Lippman SM, Hong WK. Second malignant tumors in head and neck squamous cell carcinoma: the over shadowing threat for patients with early-stage disease. Int J Radiat Oncol Biol Phys 1989; 17: 691-4.
3. Benner SE, Lippman SM, Hong WK. Chemoprevention strategies lung and upper aerodigestive tract cancer. Cancer Res 1992; 52 Suppl.: 2758s-2763s.
4. Meyskens FL, Jr. Coming of age-the chemoprevention of cancer. N Engl J Med 1990; 26. 825-7.
5. Slaughter DP, Southwick HW, Smejkal W. "Field-cancerization" in oral startification squamous epithelium: clinical implications of multicentric origin. Cancer 1953; 6: 963-8.
6. Shin DM, Gimenez IB, Lee JS, et al. Expression of epidermal growth factor receptor, polyamine levels, ornithine decarbosylase activity, micronuclei and transglutaminase I in a 7,12-dimethyl-benz [a] anthracene-incuced hamster buccal pouch carcinogenesis model. Cancer Res 1990; 50: 2505-10.
7. Lippman SM, Hong WK. "Differentiation Therapy for Head and Neck Cancer" In:Snow G, Clark R, eds. Multimodality Thereapy for Head and Neck Cancer. New York, Springer-Varlag, 1992; pp. 160-81.
8. Burge-Bottenbley A, Shklar G. Retardation of experimental oral cancer development by retinyl acetate. Nutr Cancer 1983; 5: 121-9.
9. Lippman SM, Hong WK. Retinoid Chemoprevention of Upper Aerodigestive Tract Cacinogenseis. In: De Vita VT Jr, Hellman S, Rosenberg SA, eds. Important Advances in Oncology. Philadelphia, Lippincott, 1992; pp. 91-107.
10. Licciardello JTW, Spitz MR, Hong WK. Multiple primary cancer in patients with cancer of the head and neck: second cancer of the head and neck, esophagus, and lung. Int J Radiat Oncol Biol Phys 1989; 17: 467-76.
11. Lee JS, Lippman SM, Hong WK, et al. Determination ofbiomarker for intermediate endpoints in chemoprevention trials. Cancer Res 1992; 52 (9 Suppl.):2707s-2718s.
12. Silverman S Jr, Gorsdy M, Lozada F. Oral leukoplakia and malignant transformation. A follow-up study of 257 patients. Cancer 1984; 53. 563-8.
13. Harris CC, Kaufman DG, Sporn MB, et al. Histogenesis of squamous metaplasia and squamous cell carcinoma of the respiratiory epithelium in an animal model. Cancer Chemother Rep 1973; 4. 43-7.
14. Winn DM, Ziegler RG, Pickle LW, et al. Diet in the etiology of oral and pharyngeal cancer among women from the southern United States. Cancer Res 1984; 44: 1216-22.
15. Conti CJ. Animal models in the study of the premalignant process. Cancer Bull 1991; 43: 199503.
16. Kim JS, Lee JS, Blick M, et al. Effect of retinoic acid (RA) on the gene expression, autophosphrylation, and EGF binding properties of the EGF-receptor in human head and neck squamous carcinoma cells (HNSCC) Proc Am Assoc Cancer Res 1988; 29: 42. (abstract).
17. Silverman S, Renstrup G, Pindborg JJ. Studies in oral leukoplakias III. Effect of vitamin A comparing clinical, histopathologic, cytologic, and hematology responses Acta Odontol Scand 1963; 21:271-92.
18. Hong WK, Endicott J, Itri LM, et al. EN, Vaughan C. 13-cis-retinoic acid (13cRA) maintains remission in oral premalignancy: more effective than beta-carotene in randomized trial. Proc Am Soc Clin Oncol 1990; 9: 225 (abstract).
19. Lippman SM, Toth BB, Batsakis JG. Low-dose 13-cis-retinoic acid (13cRA) maintains remission in oral premalignancy: more effective than beta-carotene in randomized trial, Proc Am Soc Clin Oncol 1990; 9: 225 (abstract).
20. Lippman SM, Hong WK. Chemoprevention of aerodigestive tract carcinogenesis. Cancer Bull 1991; 43: 525-33.
21. Stich HF, Rosin MP, Homdy AP, et al. Remission of oral leukoplakias and micronuclei in tobacco/beta quid chewers treated with beta-carotene and with beta-carotene plus vitamin A. Int J Cancer 1988; 42: 195-9.
22. Garewal HS, Meyskens FL JR, Killen D, et al. Response of oral leukoplakea to beta-carotene. J Clin Oncol 1990; 8: 1715-20.
23. Toma S, Albanese M, Delorenzi G, et al. Beta-carotene in the treatment of oral leukoplakia. Proc Am Soc Clin Oncol 1990; 9:179, (abstract).
24. Benner SE, Winn RJ, Lippman SM, et al. Regression of oral leukoplakia with alpha-tocopherol, a Community Clinical Oncology Program (CCOP) Chemnoprevention Study. I Natl Cancer Inst 1993; 85: 44-7.
25. Toma S, Coialbu T, Collecchi P, et al. Biological aspects and perspectives applicable to the chemoprevention of cancer of the upper respiratory-digestive tract. Acta Otorhinolaryngol 1990; 10 Suppl. 27: 41-54.
26. VanZandwijk N. N-Acetylcystein (NAC) in Chemoprevention. In: Pastorino U, Hong WK, eds. Chemoimmuno Prevention of Cancer. New York, Thieme Medical Publishers, 1991 ; pp. 101-4.
27. Heyne KE, Lippman SM, Hong WK. Chemoprevention in head and neck cancer. Hematol Oncol Clin North Am 1991; 5: 783-95
28. Trickier D, Shklar G. Prevention by vitamin E of experimental oral carcinogenesis. J Natl Cancer Inst 1987; 78: 195-9.
29. Goodwin WJ JR, Lane HW, Brakford K, et al. Selenium and glutathione peroxidase levels in patients with epidermoid carcinoma of the oral cavity and oropharynx. Cancer 1983; 51: 110-5.
30. DeFlora S, Astengo M, Serra D. Prevention of induced lung tumors in mice by dietary N-acetylcysteine. Cancer Lett 1986; 32: 2135.
31. Alberts DS, Coulthard SW, Meyskens FL JR. Regression of aggressive laryngeal papillomatosis with 13 cis-retinoic acid (Accutane). J Biol Response Mod 1986; 5: 124-8.
32. Bichler E. The Role of aeromatic retinoid in treatment of laryngeal keratinizing disorders and dysplasias. In: Spitzy KH, Karrer K, eds. Proceedings of the 13th International Congress of Chemotherapy. Vienna, Austria: VH Egermann 1982; pp. 201-99.
33. Corbitt G, Zarod AP, Arrand JR, et al. Human papillomavirus (HPV) genotypes associated with laryngeal papilloma. J Clin Pathol 1988; 41: 284-8.
34. Scheffner M, Werness BA, Huibregtse JM, et al. The E6 oncoprotein encoded by human papilloma types 16 and 18 promotes the degradation of p. 53. Cell 1990; 63: 1129-36.
35. Munger K, Werness B A, Dyson N, et al. Complex formation of human papillomavirus E7 protein with the retinoblastoma tumor suppressor gene product. EMBO J 1989; 20: 4099-105.
36. Bischoff JR, Friedman PN, Marshall DR, et al. Human p53 is phosphorylated by -p60-cdc2 and cyclin B-cdc2. Proc Natl Acad Sci U.S.A. 1990; 87: 4766-70.
37. Decaprio JA, Ludlow JW, Lynch D, et al. The product of the retinoblastoma susceptability gene has properties of a cell cycle regulatory element. Cell 1989; 58: 10885-95.
38. Howley PM. Mechanisms of transformation by human papilloma viruses. Proc Am Assoc Cancer Res 1991; 32: 440 (abstract).
39. Pirisi L, Batova A, Jenkins GR, et al. Increased sensitivity of human keratinocyted immortalized by human papillomavirus type 16 DNA to growth control by retinol. Cancer Res 1992; 52: 187-93.
40. Reppucci AD, Dilorenzo TP, Abramson AL, et al. In vitro modulation of human laryngeal papilloma cell differentiation by retinoic acid. Otola- A ryngol Head Neck Surg 1991; 105: 528-32.
41. Eicher SA, Taylor-Cooley LD, Donovan DT. 13-cis-retinoic acid plus interferon alpha-2a highly active systemic therapy for squamous cell carcinoma of the cervix. J Natl Cancer Inst 1992; 84: 241-5.
42. Lippman SM, Kavanagh JJ, Paredes-Espinoza M, et al. 13-cis-retmoic acid plus mterferon alpha-2a highly active systemic therapy for squamous cell carcinoma of the cervix. J Natl Cancer Inst 1992; 84: 241-5.
43. Hong WK, Lippmna SM, Itri LM, et al. Prevention of second primary tumors with isotretinoin in squamous-cell carcinoma of the head and neck. N Engl J Med 1990; 323: 795-801.
44. Lippman SM, Lee JS, Lotan R, et al. Biomarkers as intermediate endpoints in chemoprevention trials. J Natl Cancer Inst 1990; 82: 555-60.
45. Lippman SM, Peters EJ, Wargovich MJ, et al. Bronchial micronuclei as a marker of an early stage of carcinogenesis in the tracheobronchial epithelium. Int J Cancer 1990; 45: 811-5.
46. Voravud N, Shin DM, Ro JY, et al. Increased polysemies of chromosome 7 and 17 during head and neck multistage tumorigenesis. Cancer Res 1993; 53: 2874-83.
47. Field JK, Spandidos DA, Stell PM, et al. Elevated expression of the C-myc oncoprotein correlates with poor prognosis in head and neck squamous cell carcinoma. Oncogene 1989; 4: 1463-8.
48. Berenson JR, Yang J, Mickel RA. Frequent amplification of the bcl-1 locus in head and neck squamous cell carcinoma. Oncogene 1989; 4: 1111-6.
49. Somers KD, Cartwright SL, Schechter GL. Amplification of the int-2 gene in human head and neck squamous cell carcinoma. Oncogene 1990; 5: 915-20.
50. Rumsby G, Carter RL, Gusterson BA. Low incidence of ras oncogene activation in human squamous cell carcinomas. Br J Cancer 1990; 6: 365-8.
51. Shin DM, Voravud N, Ro JY, et al. Sequential increase in proliferating cell nuclear antigen expression in head and neck tumorigenesis a potential biomarker. J Natl Cancer Inst 1993; 85: 971-8.
52. Lee JS, Ro JY, Sahin A, et al. Effect of 13-cis-retinoic acid (CRA) on blood group antigen A (BGAA) expression in oral leukoplakia. Proc Am Assoc Cancer Res 1991; 32: 204 (abstract).
53. Wulf K. Zur vitamin A Behandlung Der leukoplakien. Arch Klin Exp Derm 1957; 209: 495-8.
54. Silverman S JR, Eisenberg E, Renstrup G. A study of the effects of high dose of vitamin A on oral leukoplakia (hyperkeratosis), including toxicity, liver function and skeletal metabolism. J Oral Therap Pharmacol 1965; 2: 9-23.
55. Stich HF, Hornby AP, Dunn BP. A pilot beta-carotene intervention trial with limits using sraokless tobacco. Int J Cancer 1985; 36: 321-7.
56. Stich HF, Homby AP, Mathew B, et al. Response of oral leukoplakias to the administration of vitamin A. Cancer Lett 1988; 40: 93-101.
57. Malaker K, Anderson B, Beecroft W, Hosson D. Management of oral mucosal dysplasia with beta-carotene retinoic acid: a pilot cross-over study. Cancer Detect Prev 1991; 15:335-40.
58. Ryssel HJ, Brunner KW, Bollag W. Schweiz Med Wochenschr. The oral administration of vitamin-A-acid in leukoplakias, hyperkeratoses and squamous cell carcinoma: results and tolerance. Schweiz Med Wochenschr 1971; 101: 1027-30.
59. Stuttgen G. Oral vitamin A acid therapy. Acta Derm Venereol Suppl. 1975; 74: 174-9.
60. Raque CJ, Biondo RV, Keeren MG, et al. Snuff dippers keratosis (snuff-induced leukoplakia) South Med J 1975; 68: 565-8.
61. Koch HF. Biochemical treatment of precancerous oral lesions: The effectiveness of various analogues of retinoic acid. J Maxillofac Surg 1978; 6: 59-63.
62. Koch HF. Effect of retinoids on precancerous lesions of oral mucosa. In: Orfanos CE, ed. Retinoids: Advances in Basic Research and Therapy. New York, Srpinger-Verlag, 1981; pp. 273-8.
63. Cordero AA, Allevato Mal, Barclay CA. Treatment of lichen planus and leukoplakia with the oral retinoid RO 10-9359. In: Orfanos CE, eds. Retinoids: Advances in Basic Research and Therapy. New York, Springer-Verlag, 1981; pp. 273-8.
64. Shah JP, Strong EW, DE Cosse JJ, et al. Effect of retinoids on oral leukoplakea. Am J Surg 1983; 146: 446-70.
65. Han J, Jiao L, Lu Y, et al. Evaluation of N-4-(hydroxycarbophenyl) retinamide as a cancer prevention agent and as a cancer chemotherapeutic agent. In Vivo 1990; 4: 153-6.